Novadaq Technologies and Arthrex Sign Marketing Agreement

Toronto, Canada-based Novadaq Technologies Inc., a developer of fluorescence imaging for use in surgical and diagnostic procedures, has entered a co-marketing agreement with Arthrex Inc., an orthopedic medical device company focused on arthroscopy.
 
Under the agreement, the two companies will combine expertise and devices for endoscopy in a wide variety of surgical specialties, including orthopedic, general, colorectal and gynecological surgeries. Novadaq’s “plug and play” Pinpoint upgrade kit facilitates the seamless integration of its Spy imaging technology into Arthrex’s Synergy System, combining fluorescence imaging experience with a 4K white light endoscopic system.
 
Both companies will continue to sell their own standalone systems in addition to the combined systems.
 
Naples, Fla.-based Arthrex will have the ability to include the Pinpoint upgrade kit in all new Synergy System purchases, as well as upgrade its existing installed base. Novadaq’s sales team will continue to sell Pinpoint as a part of its fluorescence imaging ecosystem, and Novadaq also will supply the disposable kits required to perform Spy imaging procedures directly to Arthrex customers that have purchased Pinpoint upgrade kits.
 
“Arthrex is excited to be involved with this unique collaboration. Partnering with Novadaq to provide the market with Pinpoint, the market leading florescence imaging system and Synergy UHD4, the world’s first 4K endoscopic visualization platform, will provide an optimal solution for hospitals and surgery centers. Both companies are dedicated to clinically relevant, outcome based medicine focused on patients,” said Steve Jones, Vice President of Marketing, Arthrex California
Technology, Inc.
 
“Arthrex is a word-class medical device company committed to innovation, medical education and patient care,” said Rick Mangat, Novadaq’s senior vice president and general manager. “We are excited to collaborate with Arthrex through this innovative co-marketing structure to bring the benefits of Novadaq’s fluorescence imaging to their customer base and expand adoption of Novadaq’s technology into additional markets.”
 
Novadaq’s Spy fluorescence imaging technology provides surgeons with real-time visualization, leading to improved outcomes and reduced costs without exposing the patient to radiation. According to the company, more than 140 peer-reviewed publications demonstrate that the use of Spy imaging technologies during complex surgery and diagnostic procedures, leads to lower rates of post-operative complications and lower hospital costs.
 
Spy imaging systems are U.S. Food and Drug Administration 510(k) cleared for use in seven surgical specialties. The endoscopic version of Spy, called Pinpoint, combines the capabilities of Spy imaging with high-definition visible light visualization offered by conventional endoscopes, according to the company. The company’s Luna device is used to assess perfusion in patients being treated for non-healing wounds.